Beam Therapeutics Inc. (BEAM)
NASDAQ (NGS) NASDAQ (NGS) Primary 
XMEX 
Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress
Beam Therapeutics is reaffirmed as a long-term buy, with significant upside expected around 2028–2029 as BEAM-302 advances. BEAM's pipeline leadership in AATD gene editing (BEAM-302) offers first-mover advantage, while Risto-cel's blockbuster potential is now downgraded. AI-driven competition, such as Anthropic, is unlikely to disrupt BEAM in the near term; partnerships with AI firms could become a future catalyst.
Beam Therapeutics Inc. (BEAM) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Beam Therapeutics Inc. (BEAM) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
3 Promising Genomics Stocks in the Spotlight in 2026
Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.
BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus
Beam Therapeutics posts a wider-than-expected Q2 loss. Revenues also miss estimates as it advances multiple genome-editing programs with key clinical milestones ahead.
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Lags Revenue Estimates
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.18 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to a loss of $1 per share a year ago.
Beam Therapeutics: A Valuation With Upside Left
Beam Therapeutics offers compelling upside, with a $2.64B market cap and a promising gene-editing pipeline spanning hematology and liver-targeted diseases. Lead programs Risto-cel, BEAM-302, and BEAM-301 demonstrate superior or competitive efficacy and safety profiles versus key competitors, supporting significant commercial potential. BEAM's $1.2B liquidity provides a cash runway well into 2029, with additional revenue from collaborations, notably with Eli Lilly and Pfizer.
BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria
Beam Therapeutics gains after the FDA clears the IND for BEAM-304 in PKU, advancing its liver-targeted gene-editing program into clinical testing.
Beam Therapeutics Stock Soars 21% in Three Months: Here's Why
BEAM shares jump 21% in three months as promising BEAM-302 data, pipeline milestones and a cash runway into mid-2029 boost investor confidence.
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.
Beam Therapeutics Inc. (BEAM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Beam Therapeutics Inc. (BEAM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances
Beam Therapeutics NASDAQ: BEAM Chief Executive Officer John Evans said the company is advancing its base-editing platform across hematology and liver disease programs, with a potential biologics license application for its sickle cell disease candidate possible as early as the end of this year.
